About Spruce Biosciences, Inc. - Common Stock (SPRB)
Spruce Biosciences Inc is a biopharmaceutical company focused on the development of innovative therapies for patients with rare endocrine disorders. The company is committed to addressing unmet medical needs through the advancement of its proprietary drug candidates, particularly targeting conditions related to adrenal insufficiency. By harnessing cutting-edge scientific research and clinical expertise, Spruce aims to bring effective treatment options to patients, ultimately enhancing their quality of life and managing complex hormonal imbalances associated with these disorders. Read More
Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced the company’s new corporate strategy and acquisition of tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB).
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological and endocrine disorders with significant unmet medical need, today announced topline results from its CAHmelia-204 study of tildacerfont in adult CAH and its CAHptain-205 study of tildacerfont in adult and pediatric CAH.
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and neurological disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2024 and provided corporate updates.
